Back to search results

Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Malignant Pleural Mesothelioma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Antwerp University Hospital, Edegem, Antwerp, Belgium

    Contact: Study coordinator (Zwi N Berneman, MD, PhD) · zwi.berneman@uza.be

  • AZ Maria Middelares, Ghent, Belgium

    Contact: Study coordinator (Paul Germonpré, MD, PhD)

  • VITAZ, Sint-Niklaas, Belgium

    Contact: Study coordinator (Koen Deschepper, MD)
Study leads

  • Zwi N Berneman, MD, PhD

    Study Director

    Antwerp University Hospital, Division of Hematology and Center for Cell Therapy and Regenerative Medicine

  • Paul Germonpré, MD, PhD

    Principal Investigator

    AZ Maria Middelares, Respiratory Oncology & Integrated Cancer Center Ghent

  • Koen Deschepper, MD

    Principal Investigator

    VITAZ, Division of Pulmonary and Infectious Diseases

View source on ClinicalTrials.gov(opens in a new tab)